Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease.

ABSTRACT: Alzheimer's disease (AD) is the prevailing cause of age-associated dementia worldwide. Current standard of care relies on antibody-based immunotherapy. However, antibody-based approaches carry risks for patients, and their effects on cognition are marginal. Increasing evidence suggests that T cells contribute to AD onset and progression. Unlike the cytotoxic effects of CD8⁺ cells, CD4⁺ T cells capable of regulating inflammation show promise in reducing pathology and improving cognitive outcomes in mouse models of AD and in aging. Here, we sought to exploit the beneficial properties of CD4⁺ T cells while circumventing the need for TCR and peptide-MHC antigen discovery, thereby providing a potential universal therapeutic approach. To achieve this, we engineer

SUBMITTER: Boskovic P 

PROVIDER: S-EPMC12912999 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature